Kunwoo Lee is the CEO and Co-founder of BreezeBio (formerly GenEdit), a Brisbane, California-based biotech company pioneering non-viral gene delivery through its proprietary NanoGalaxy platform. A Siebel Scholar and Forbes 30 Under 30 honoree who earned his PhD from UC Berkeley-UCSF Joint Program in Bioengineering, Lee co-founded GenEdit in 2016 alongside Professor Niren Murthy and fellow researcher Hyo Min Park, building out a polymer nanoparticle library of thousands of chemically distinct compounds capable of delivering diverse genetic payloads to specific tissues. The company has raised over $118 million including a $60M Series B in February 2026, struck a landmark $644M collaboration deal with Genentech, and rebranded to BreezeBio to signal its pivot from platform company to clinical-stage therapeutics developer advancing BRZ-101 for Type 1 Diabetes.
Morgan Beller is a General Partner at NFX, the seed-stage venture firm known for backing network-effects businesses. Before VC, she co-founded Facebook's Libra (later Diem) digital currency project at age 25, making her one of the most consequential figures in crypto policy history. A Cornell statistics graduate, she cut her teeth at Andreessen Horowitz before stints at Medium and Facebook, where her geopolitical alarm about China's digital currency ambitions drove her to attempt something audacious: rebuild global money on a blockchain. She now backs founders in crypto, fintech, AI, and space from San Francisco.